| Basics |
Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.
|
| IPO Date: |
February 19, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.18B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 3.01%
|
| Avg Daily Range (30 D): |
$0.20 | 1.84%
|
| Avg Daily Range (90 D): |
$0.19 | 1.79%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.36M |
| Avg Daily Volume (30 D): |
1.35M |
| Avg Daily Volume (90 D): |
1.47M |
| Trade Size |
| Avg Trade Size (Sh.): |
184 |
| Avg Trade Size (Sh.) (30 D): |
88 |
| Avg Trade Size (Sh.) (90 D): |
86 |
| Institutional Trades |
| Total Inst.Trades: |
4,491 |
| Avg Inst. Trade: |
$2.39M |
| Avg Inst. Trade (30 D): |
$2.11M |
| Avg Inst. Trade (90 D): |
$2.34M |
| Avg Inst. Trade Volume: |
.19M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.94M |
| Avg Closing Trade (30 D): |
$2.36M |
| Avg Closing Trade (90 D): |
$2.98M |
| Avg Closing Volume: |
248.71K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.44
|
$.16
|
$-.77
|
|
Diluted EPS
|
$-.46
|
$.14
|
$-.77
|
|
Revenue
|
$ 316.27M
|
$ 95.44M
|
$ 68.16M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -52.73M
|
$ 18.72M
|
$ -96.1M
|
|
Operating Income / Loss
|
$ -.75M
|
$ 14.43M
|
$ -23.63M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -13.37M
|
$ 47.41M
|
$ -44.15M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 10, 2014:
1:10
|
|
|
|
